A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting by Files, D.C. et al.
A Critical Role for Muscle Ring Finger-1 in Acute Lung
Injury–associated Skeletal Muscle Wasting
D. Clark Files1,2, Franco R. D’Alessio1, Laura F. Johnston1, Priya Kesari1, Neil R. Aggarwal1,
Brian T. Garibaldi1, Jason R. Mock1, Jessica L. Simmers3, Antonio DeGorordo1, Jared Murdoch1,
Monte S. Willis4, Cam Patterson4, Clarke G. Tankersley5, Maria L. Messi6, Chun Liu2,
Osvaldo Delbono6, J. David Furlow7,8, Sue C. Bodine7,8, Ronald D. Cohn3, Landon S. King1,
and Michael T. Crow1
1Division of Pulmonary and Critical Care Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland; 3McKusick-Nathans Institute of
Genetic Medicine, Baltimore, Maryland; 4McAllister Heart Institute, University of North Carolina, Chapel Hill, North Carolina; 5Department of
Environmental Health Sciences, School of Public Health, Johns Hopkins University, Baltimore, Maryland; 6Department of Internal Medicine-
Gerontology and 2Internal Medicine-Pulmonary, Critical Care, Allergy and Immunology, Wake Forest University School of Medicine, Winston-Salem,
North Carolina; and 7Department of Neurobiology, Physiology, and Behavior, and 8Department of Physiology and Membrane Biology, University of
California, Davis, California
Rationale: Acute lung injury (ALI) is a debilitating condition associated
with severe skeletalmuscleweakness thatpersists inhumans longafter
lung injury has resolved. The molecular mechanisms underlying this
condition are unknown.
Objectives: To identify themuscle-specificmolecularmechanisms re-
sponsible for muscle wasting in a mouse model of ALI.
Methods:Changesinskeletalmuscleweight,fibersize, invivocontractile
performance, and expression ofmRNAs and proteins encodingmuscle
atrophy–associated genes for muscle ring finger-1 (MuRF1) and atro-
gin1weremeasured.Genetic inactivationofMuRF1orelectroporation-
mediated transduction of miRNA-based short hairpin RNAs targeting
either MuRF1 or atrogin1 were used to identify their role in ALI-
associated skeletal muscle wasting.
Measurements and Main Results: Mice with ALI developed profound
muscle atrophy and preferential loss of muscle contractile proteins as-
sociatedwith reducedmuscle function in vivo. AlthoughmRNAexpres-
sion of the muscle-specific ubiquitin ligases, MuRF1 and atrogin1, was
increased in ALI mice, only MuRF1 protein levels were up-regulated.
Consistent with these changes, suppression of MuRF1 by genetic or
biochemical approaches preventedmuscle fiber atrophy,whereas sup-
pression of atrogin1 expression was without effect. Despite resolution
of lung injury and down-regulation ofMuRF1 and atrogin1, force gen-
eration in ALI mice remained suppressed.
Conclusions: These data show thatMuRF1 is responsible formediating
muscleatrophy thatoccursduringtheperiodofactive lung injury inALI
mice and that, as in humans, skeletal muscle dysfunction persists de-
spite resolution of lung injury.
Keywords: skeletal muscle atrophy; intensive care unit–acquired weakness;
critical illness myopathy; muscle atrophy genes; proteasomal-mediated
protein degradation
Acute lung injury (ALI) is a syndrome characterized by the acute
onset of pulmonary infiltrates and respiratory failure often lead-
ing to the need for mechanical ventilation (1). Approximately
200,000 people per year develop ALI in the United States, with
mortality high at 30–40% (2). A common complication associ-
ated with ALI is skeletal muscle weakness. Weakness in these
patients results in decreased long-term mobility and functional
status. Skeletal muscle weakness is initiated early in the course
of ALI, and has been shown to persist in a large percentage of
patients for up to 5 years after resolution of lung injury and
hospital discharge (3–6). Although multiple factors may con-
tribute to ALI-induced muscle atrophy including reduced nutri-
tion, inactivity caused by bed rest, and systemic inflammation,
the etiology of ALI-associated skeletal muscle atrophy remains
incompletely understood.
Skeletal muscle weakness is a common finding not only
among patients with ALI, but also in patients with other critical
illnesses. Clinically apparent weakness is present in 20–50% of
patients with critical illness and has been shown to be an inde-
pendent risk factor for mortality in these patients (3, 5, 7, 8). A
variety of terms have been used in the literature to describe the
myopathic weakness in these patients including acute quadri-
plegic myopathy, critical illness myopathy, and thick filament
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Muscle weakness contributes to the mortality and long-term
morbidity of acute lung injury (ALI) in patients. There are
currently no reported animalmodels ofALI-associated skeletal
muscle wasting or established molecular mechanisms of how
such wasting occurs.
What This Study Adds to the Field
We present a mouse model of ALI-associated skeletal muscle
wasting that replicates many of the features of ALI-associated
skeletal muscle wasting in humans and show that the muscle-
specific E3 ubiquitin ligase, known as muscle ring finger-1, is
a critical mediator of the ALI-associated skeletal muscle
wasting that occurs in this model.
 
myopathy, the latter referring to the preferential loss of myosin
observed in the muscles of these patients (9–11).
Studies over the last 12 years have defined important roles
for muscle-specific genes that regulate muscle wasting in well-
defined models of skeletal muscle atrophy, including immobili-
zation, denervation, and hindlimb suspension (12). Prominent
among these are the genes Fbx032 (atrogin1 or MAFbx) and
Trim63 (muscle ring finger protein-1 [MuRF1]), both of which
function as ubiquitin E3 ligases in the proteasome-mediated
degradation of skeletal muscle proteins (12, 13). Up-regulation
of MuRF1 and atrogin has also been observed in the peripheral
muscles of patients with chronic obstructive pulmonary disease
and in the diaphragms of mechanically ventilated brain-dead
patients (14, 15).
In this study, we used a mouse model of ALI to define the
molecular mechanisms responsible for ALI-induced muscle
wasting. This model of direct lung injury is highly reproducible
and proceeds through distinct injury and resolution phases over
a relatively short time course (16). Our data show that there is
a marked up-regulation of MuRF1 and atrogin1 gene expres-
sion in ALI mice within 2–3 days after inducing lung injury
and, as in human ALI, contractile dysfunction triggered by
ALI that persists despite down-regulation of MuRF1 and
atrogin1 gene expression and complete resolution of lung in-
jury. We tested the hypothesis that MuRF1 is necessary for the
ALI-associated decrease in muscle mass and loss of contractile
proteins during the period of active lung injury. Some of the




All animal experiments were conducted under protocols approved by
the Johns Hopkins Animal Care and Use Committee. Eight-week-old
male C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were
housed in a pathogen-free facility. To induce lung injury, mice were
anesthetized with an intraperitoneal (IP) injection of 150 mg/kg ket-
amine and 13.5 mg/kg acetylpromazine and the trachea exposed.
Escherichia coli LPS (O55:B5 L2880; Sigma-Aldrich, St. Louis,
MO) at 3 mg/g mouse or an equivalent volume of sterile H2O (sham
control) was then instilled intratracheally using a 20-gauge catheter.
Animals were not mechanically ventilated and oxygenation or activity
levels were not monitored. For IP-LPS studies, mice were given 3 mg/g
LPS IP and harvested at subsequent time points. Breeding pairs
of MuRF11/2 mice were provided by Drs. Cam Patterson and Monte
Figure 1. Acute lung injury (ALI) induces
body weight loss, reduced food consump-
tion, and muscle weakness. Bronchoalveo-
lar lavage fluid (BALF) of ALI (intratracheal
[IT]-LPS) and sham (IT-H2O) mice revealed
an increase in total cell count (A) and total
protein (B) that peaked between Days 3
and 4 in ALI mice and returned to baseline
by Day 10. *P , 0.03 versus baseline val-
ues; n ¼ 5–6. Based on these data and the
accompanying histology of the lungs (see
Figure E1), we refer to the period between
Days 1 and 4 after IT-LPS as the “lung in-
jury phase” and between Days 4 and 10 as
the “lung resolution phase.” (C) ALI mice
have an approximate 20% drop in body
weight (BW) 3 days after IT-LPS. yP ,
0.001; n ¼ 5. (D) Food consumption dra-
matically falls in ALI mice after IT-LPS (open
triangles) compared with sham-operated
mice (black circles). zP , 0.01. (E) Pair-fed
(PF) mice were used to control for the
effects of reduced food consumption. These
mice underwent a sham surgery (IT-H2O)
and had food intake matched to that con-
sumed by ALI mice on a daily basis. The
data in the bar graphs show that cumulative
food intake over the 10 days of lung injury
and resolution was equal in PF and ALI
mice. zP , 0.01. (F) Whole body weight
loss profiles were similar in PF (gray circles)
and ALI mice (open triangles) but signifi-
cantly different from changes in the body
weights of shammice (black circles) (analysis
of variance, P , 0.001 for group differen-
ces), except for Day 3. xP , 0.03; n ¼ 5.
(G) Despite similar body weight losses, ALI
mice had reduced grip strength compared
with PF mice (analysis of variance, P ,
0.001). Data are expressed as means 6
SEM. *P , 0.001, ALI versus PF; P ¼
0.008, sham versus ALI; P ¼ 0.014, sham
versus PF. n ¼ 8–10 in each group.
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Willis of the McAllister Heart Institute at the University of North
Carolina.
Bronchoalveolar Lavage and Analysis
At specified times after instillation, mice were anesthetized, blood or
bronchoalveolar lavage fluid (BALF) removed, and the animals then
killed by exsanguination. BALF counts and protein analyses were per-
formed as previously described (16).
Lung Histology
Lungs were inflated to 25 cm H2O with 1% low-melting agarose (Invi-
trogen, San Diego, CA); fixed in 10% formalin; then embedded in
paraffin and sectioned for histologic evaluation by hematoxylin and
eosin staining (20).
Measurement of Plasma Levels of LPS
Blood was collected retroorbitally from mice at 6, 24, and 72 hours after
intratracheal (IT) H2O, IT-LPS, or IP-LPS administration and then
placed in ethylenediaminetetraacetic acid–coated tubes. Mice were
then killed by administration of ketamine and acepromazine followed
by cervical dislocation. The blood was prepared for measurements of
LPS (Limulus assay) levels, according to the manufacturer’s instruc-
tions (Hycult Biotech, Plymouth Meeting, PA).
Mouse Grip Strength
Mouse grip strength was measured using a grip strength meter (Co-
lumbus Instruments, Columbus, OH) and the peak force generated
from one of five successive trials was recorded as described previously
(21).
Statistical Evaluation of Data
Data are expressed as the mean 6 SEM or median and interquartile
ranges. Unpaired Student t test, analysis of variance, or the Mann-
Whitney test was used for statistical comparisons when appropriate.
Differences were considered significant at P less than 0.05.
Additional methods for reverse transcriptase quantitative polymer-
ase chain reaction, Western blotting, in vivo force measurements, plas-
mid generation, and skeletal muscle electroporation are provided in
the online supplement.
Figure 2. Acute lung injury (ALI) and pair-fed
(PF) mice develop skeletal muscle atrophy. (A)
Tibialis anterior (TA) muscle wet weights were
decreased in PF and ALI mice by Day 3 post–
intratracheal (IT)-LPS. *P , 0.003; n ¼ 6. (B)
Cross-sections of TA muscles from sham, ALI,
and PF mice at Day 4 post–IT-LPS. Muscle fibers
were identified by sarcolemmal staining for
g-laminin. Scale bar ¼ 100 mm. (C) Mean fiber
diameters of sham, PF, and ALI from Day 4 mice.
*P, 0.003; n ¼ 5. (D) Combined myosin ATPase
histochemistry (alkaline preincubation) and
g-laminin staining enabled independent fiber
size measurements of type I (light staining) and
type II (dark staining) muscle fibers in the soleus.
(E) Summary of mean muscle fiber diameters
segregated by experimental group and muscle
fiber type. Data are expressed as means 6
SEM. xP , 0.03; zP , 0.02. Scale bar as in (B).
(F) Force-frequency curves for Day 4 sham, PF,
and ALI hindlimb muscles showing reduced con-
tractile force production in PF and ALI mice. (G)
Specific force–frequency curves for Day 4 sham,
PF, and ALI mice. Normalization of force to mus-
cle mass for all three groups shows no difference
in contractile performance.
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RESULTS
IT-LPS Causes ALI and Reduced Muscle Function
As described previously (16, 22, 23) and shown in Figure E1 in
the online supplement, IT-LPS induced within 3 days a pattern
of lung injury that was distinguished by severe alveolar consoli-
dation with cellular infiltrates and interstitial thickening. At 7 days
post–IT-LPS, lung injury had nearly resolved, and by Day 10 the
lungs appeared normal. Total BALF cell counts and protein levels
(Figures 1A and 1B) followed a similar time course, rising during
the period of active lung injury (Days 1–4) and returning to base-
line during the lung recovery and resolution phases (Days 5–10).
Sham mice receiving IT-H2O and then killed at Day 3 showed no
evidence of lung injury (sham data points, Figures 1A and 1B).
Data in the literature and experiments described in Figure E2
suggest that this IT-LPS model differs significantly in its pharma-
cokinetics from IP-LPS models of sepsis (22, 23).
Within 3 days after the administration of IT-LPS tomice (here-
after referred to asALImice), there was an approximate 20% loss
in body weight (Figure 1C). Because loss of body weight could be
caused in part or in whole by the marked reduction in food
intake by ALI mice (Figure 1D), we generated pair-fed (PF)
mice to control for this effect (Figure 1E). Importantly, despite
similar weight loss profiles in PF and ALI mice (Figure 1F), only
ALI mice exhibited a significant drop in muscle force production
as measured by a grip strength meter (Figure 1G).
Reduced Muscle Function Is Associated with Skeletal
Muscle Atrophy
To assess muscle atrophy in sham, PF, and ALI mice in response
to lung injury, we first measured the wet weights of the tibialis
anterior (TA)muscles. TAwet weights in PF andALImice were
significantly lower than in sham mice (Figure 2A). To elucidate
the mechanisms underlying these losses, we measured the size
distribution of muscle fibers sorted by diameter as described in
the online supplement. Figure 2B shows images of cryosections
with the sarcolemmae delineated by g-laminin immunofluores-
cence chemistry. Figure E3 shows a histogram of the size distri-
bution of fiber diameters and Figure 2C the mean fiber
diameters from each of the three groups. These data reveal that
mean fiber diameters of ALI and PF mice were statistically
different from time-matched controls but not from each other
(Figures 2B and 2C).
To determine if different muscle fibers are differentially af-
fected byALI,mean fiber diameters of types I and IImuscle fibers
were assessed using the soleus muscle, because the TAmuscle has
few type I fibers. Staining of the muscles to identify type I (light
Figure 3. Myosin heavy chain (MHC) degradation,
ubiquitination, and increased muscle atrogene expres-
sion in pair-fed (PF) and acute lung injury (ALI) mice.
(A) Western blots showing sarcomeric MHC abun-
dance in sham, PF, and ALI mice and MHC from ALI
muscle ring finger-1 (MuRF1)2/2 mice (top). Quantifi-
cation of expression normalized to glyceraldehyde
phosphate dehydrogenase (GAPDH) expression (bot-
tom). (B) Western blot of extracts from sham, PF, and
ALI muscles show a marked increase in high molecular
weight (HMW) polyubiquinated proteins (top). Quantifica-
tion of expression expressed in arbitrary units (bottom).
Results of quantitative reverse transcriptase polymerase
chain reaction measurements of MuRF1 (C) and atrogin1
(D) mRNA expression in muscles from PF and ALI mice
versus expression in sham mice. *P , 0.02; n ¼ 5–8. (E
and F) Time course of MuRF1 and atrogin1 protein expres-
sion in PF and ALI mice. PF mice exhibit a relatively weak
expression of MuRF1 proteins, whereas up-regulation of
MuRF1 protein in ALI is much stronger. Neither PF nor
ALI muscles exhibit any change in atrogin1 protein levels
at any time and under any condition tested. *Possible
processing intermediates of MuRF1.
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gray) and II (dark gray) fibers is shown in Figure 2D and the
mean fiber distribution of types I and II fibers is summarized in
Figure 2E. The results show that type II muscle fibers are differ-
entially affected by ALI-induced muscle wasting.
Because grip strengthmeasurements reflect not only the contrac-
tile properties of the muscle, but also neurogenic and behavioral
effects, we also measured muscle force production elicited by in
situ stimulation of the peritoneal nerve. Day 4 PF and ALI mice
showed a similar reduction in absolute force generation compared
with sham mice (Figure 2F). Specific force generation (absolute
force normalized to muscle mass), however, was the same for all
three groups (Figure 2G), suggesting that decreased force gener-
ation in ALI and PF mice at Day 4 may be directly caused by loss
of muscle mass alone (Figure 2A).
MuRF1 Protein Levels Are Differentially Regulated in ALI
and PF Mice
Although loss of muscle mass and mean fiber diameter were sim-
ilar in PF and ALI mice during the period of active lung injury
(Days 2–4), an analysis of the molecular changes occurring in
these mice revealed substantial qualitative differences. Figure
3A shows that the expression of sarcomeric muscle myosin
heavy chain (MHC) proteins was suppressed in PF mice and
even more so in ALI mice. Because striated MHCs are well-
described targets for degradation by the ubiquitin-proteasomal
system (24), we measured levels of polyubiquinated proteins in
the three experimental groups (Figure 3B) and found that they
were increased in ALI but not PF mice. The blot in Figure 3B
shows extensive ubiquitination of proteins coincident with sar-
comeric MHCs.
Two of the most common genes up-regulated in muscle wast-
ing are Trim63 (MuRF1) and Fbxo32 (atrogin1) (12, 13, 25–27).
These proteins function as muscle-specific ubiquitin E3-ligases that
tag proteins for the ubiquitin-proteasomal pathway. Figures 3C and
3D show that MuRF1 and atrogin1 mRNA expression were mark-
edly up-regulated in the TAmuscles of ALI mice, but only modestly
up-regulated in PF muscles. Expression of MuRF1 protein followed
a pattern similar to its mRNA, higher in ALI muscles (Figure 3F)
and lower in PF muscles (Figure 3E), whereas the expression of
Figure 4. Muscle wasting in muscle ring
finger-1 (MuRF1)2/2 mice and increased
nuclear factor (NF)-kB activity in acute
lung injury (ALI) wild-type (WT) mouse
muscles. (A) Western blot of MuRF1 pro-
tein expression shows up-regulation in
ALI MuRF1 WT but no up-regulation in
ALI MuRF12/2 mouse muscles. GAPDH ¼
glyceraldehyde phosphate dehydroge-
nase; PF ¼ pair fed. (B) Mean fiber diame-
ters for WT and MuRF12/2 tibialis anterior
(TA) muscles show a moderate increase in
mean muscle fiber diameters in sham con-
trol MuRF12/2 mice. Exposure to ALI
markedly reduces mean muscle fiber di-
ameter in WT muscles mice but only
a slight reduction in the MuRF12/2 mus-
cle. *P¼ 0.004; yP¼ 0.007; #P¼ 0.03. (C)
Histograms of the fiber distribution of
sham and ALI-treated MuRF11/1 (WT)
muscles reveal a large shift to the left
(smaller size). (D) Histograms of the fiber
distribution of sham and ALI-treated
MuRF12/2 (knockout) muscles show only
a small shift to the left and smaller fiber
diameters. (E) Assessment of ALI-induced
muscle transcriptional activity was mea-
sured by electroporating plasmids in which
firefly luciferase transcription was con-
trolled by transcriptional response ele-
ments specific for glucorticoid signaling
(4XGRE-luc), FOXO signaling (3XFBE-luc),
and NF-kB signaling (3XNf-kB-luc). Only
increases in FBE- and NF-kB–luciferase ac-
tivity is significantly up-regulated in ALI. (F)
Luciferase reporter for MuRF1 transcrip-
tional activity containing either no NF-kB
binding elements (500 MuRF1-luc) or mul-
tiple NF-kB binding sites (5,000 MuRF-luc).
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atrogin1 protein was not affected by any condition. Data in Figure
E4 show that MuRF1 and atrogin1 mRNA expression were also
up-regulated in the diaphragms from Day 3 ALI mice.
MuRF1 Is Necessary for Skeletal Muscle Wasting during
the Period of ALI
Because the previously mentioned data reveal a strong association
of MuRF1 mRNA and protein expression with ALI-associated
skeletal muscle wasting, we tested MuRF1’s role in ALI-
associated muscle wasting in MuRF12/2 (knockout [KO]) mice.
We probed muscle extracts from sham, PF, and ALI wild-type
(WT) mice and ALI KO mice and found, as expected, that
MuRF1 expression increased only in ALI WT mice (Figure 4A).
The mean fiber diameter of the TA muscle in untreated MuRF1
KO mice at baseline was slightly larger than in untreated WT
mice (Figure 4B). Although ALI resulted in a reduction of the
mean fiber diameter of greater than 25% in WT mice, the reduc-
tion in mean muscle fiber diameter in MuRF1 KO ALI mice was
less than 5% and not significantly different from the mean muscle
fiber diameter in untreated WT mice. These data show that the
up-regulation of MuRF1 is required for ALI-induced skeletal
muscle wasting.
We then searched for signaling pathways that are preferentially
activated during lung injury and capable of driving increased
MuRF1 transcription in ALI muscles. Other studies have impli-
cated signaling through glucocorticoid receptors, FOXO proteins,
and nuclear factor-kB (NF-kB) transcriptional activity as impor-
tant regulators of muscle wasting (28–31).We introduced plasmids
reporting on each of these pathways into TAmuscles and assessed
their activity 3 days after either sham or ALI treatment. The data
in Figure 4E show that reporter activity for glucocorticoid signal-
ing (4XGRE-luc) was not up-regulated in ALI mice, whereas
FOXO (3XFBE-luc) and NF-kB (3XNF-kB-luc) signaling were
increased by more than 5- and 25-fold, respectively. To determine
if the marked up-regulation of NF-kB activity in ALI mice was
linked to MuRF1 gene transcription, we compared the ALI-
induced activation of two different MuRF1 promoter constructs,
one lacking the all NF-kB binding sites (2500 MuRF1) and the
other containing multiple NF-kB sites (25,000 MuRF1). The data
in Figure 4F show that the 5,000 MuRF1 reporter construct was
activated nearly 50-fold in ALI muscles, more than 10 times that
of the 500 MuRF1 reporter. These results show that NF-kB ac-
tivity is markedly and selectively up-regulated in ALI muscles and
that this up-regulation drives increased MuRF1 transcription.
Suppression of Muscle Wasting in ALI Mice by
Plasmid-based shRNAs
To control for potential developmental effects of congenitally
decreasedMuRF1 expression inMuRF1KOmice, we also trans-
duced plasmids coexpressing Emerald GFP (EmGFP) and
miRNA-based short hairpin (sh) RNAs directly into TAmuscles
by electroporation. Figures E5 and E6 show the relative effec-
tiveness of these shRNAs in cells expressing mouse MuRF1
or atrogin, respectively. One week later, the mice were randomly
assigned to sham, PF, or ALI treatment groups and the muscles
harvested 4 days later for analysis. From EmGFP expression, we
determined that 70–80% of the muscle fibers in the mouse TA
were transduced using our modification of the muscle electro-
poration technique (see Figure E7). Biochemical analyses of the
entire muscle revealed an approximate 70% reduction in
MuRF1 protein levels in MuRF1 shRNA-transduced muscles
compared with muscles transduced with the EmGFP and a neg-
ative control shRNA (Figure 5A). With an overall in vivo trans-
duction efficiency of 70–80%, MuRF1 protein levels in MuRF1
shRNA-transduced muscle fibers should be reduced by approx-
imately 75–85%.
Figure 5. Muscle ring finger-1 (MuRF1) miRNA-based
short hairpin (sh) RNAs effectively blocks MuRF1 pro-
tein expression in pair-fed (PF) and acute lung injury
(ALI) mice but increases myosin heavy chain (MHC)
content only in acute lung injury (ALI) mice. (A) Immu-
noblots of MuRF1 and glyceraldehyde phosphate de-
hydrogenase (GAPDH) from muscles transduced with
Emerald GFP (EmGFP)-Neg control (NEG) shRNA or
EmGFP-MuRF1 shRNA show that MuRF1 expression is
reduced by approximately 70% in MuRF1 shRNA
muscles. *P, 0.008. (B) Knockdown of MuRF1 protein
by the EmGFP-MuRF1shRNA plasmid increased MHC
content in ALI mice but had no effect on MHC levels in
PF mice. Dotted line in B represents MHC level in con-
trol (EmGFP-Neg shRNA) muscles. yP ¼ 0.03. (C) Dif-
ferences in tibialis anterior (TA) muscle mass in muscle
transduced with EmGFP-MuRF1 shRNA, with results
expressed with reference to EmGFP-Neg shRNA. (D)
In situ force–frequency curves for muscles transduced
with EmGFP-Neg and EmGFP-MuRF shRNAs and ana-
lyzed at Day 10. Data show an increase in force pro-
duction by MuRF1 shRNA versus NEG shRNA. P ¼
0.023.
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Using this approach, we found that the MuRF1 shRNA 520
effectively prevented muscle wasting in ALI muscles. First, we
found that MuRF1 shRNA treatment in ALI mice significantly
increasedMHC expression but had no effect onMHC expression
in PF mice (Figure 5B). In four out of five ALI mice, treatment
with MuRF1 shRNA showed a trend toward increased TA mus-
cle weight compared with the contralateral (Neg-shRNA) limb.
In PF mice, the trend was toward a decrease in muscle weight
with MuRF1 shRNA (Figure 5C). We also measured force pro-
duction in ALI-MuRF1 shRNA and ALI-Neg shRNA mice.
Although we found no change in force production at Day 4
post–IT-LPS (data not shown), we did observe a modest but
significant restoration of force production with MuRF1 shRNA
at Day 10 post–IT-LPS (Figure 5D). In addition, although the
mean diameter of EmGFP-positive muscle fibers was unaffected
in MuRF1 shRNA transduced muscles from sham and PF mice,
there was a large rightward shift in fiber size distribution (in-
creased muscle fiber diameter) and a statistically significant in-
crease in mean fiber diameter in MuRF1 shRNA transduced
muscles from ALI mice (Figures 6A, 6B, and 6D). We repeated
this series of experiments using a second MuRF1 shRNA (610;
see Figure E5) targeting a different region of the mouse MuRF1
coding sequence and obtained near-identical results.
We also constructed two plasmids encoding EmGFP and one
of two atrogin1 shRNAs (384 and 534), which were transduced
into the TA muscles of ALI mice (see Figure E6). In contrast to
the results seen with the MuRF1 knockdown, however, knock-
down of atrogin1 had no effect on ALI-associated muscle atro-
phy (Figures 6C and 6D). Together, these results show that
inhibition of MuRF1, but not atrogin1, abrogates muscle fiber
atrophy in ALI mice.
ALI Muscle Wasting Persists Despite Resolution of
Lung Injury
Although data presented in Figures 1A and 1B and Figures E1
and E2 show that lungs are fully recovered from ALI by Day 10,
mean fiber diameters in PF and ALI remained suppressed
Figure 6. Muscle ring finger-1
(MuRF1) regulates muscle atro-
phy in acute lung injury (ALI)
mice. Emerald GFP (EmGFP)-
Neg shRNA or EmGFP-MuRF1
shRNAs were electroporated in-
to the tibialis anterior (TA)
muscles. One week later, mice
underwent sham, pair-fed (PF),
or ALI treatments. (A) Muscles
were fixed at harvest and the
sarcolemma stained with an
antibody to dystrophin (red)
to measure diameters of fibers
expressing EmGFP. Scale ¼
100 mM. (B) Fiber histograms
of sham, PF, and ALI mice trea-
ted with EMGFP-MuRF1 shRNA
or EmGFP-Neg shRNAs. (C) The
same technique was used to
electroporate EmGFP-atrogin1
shRNA into the TA of ALI mice.
(D) Mean fiber diameters of
sham, PF, and ALI mice treated
withMuRF1 or atrogin1 shRNAs.
Fiber diameter is restored to
sham conditions in ALI mice
treated with MuRF1 shRNA but
not atrogin1 shRNA. Data are
expressed as means 6 SEM.
*P, 0.006; n¼ 5 in each group.
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(Figures 7B and 7C). Wet weights of the PF and ALI muscles
were, however, similar to sham control levels (Figure 7A). Al-
though data in Figures 3E and Figure 7D show that Day 10
MuRF1 protein levels have been at baseline for several days,
MHC protein levels remain depressed (Figure 7D). Absolute
force production from the TA at Day 10 is similar in sham and
PF mice, whereas force production in ALI mice is markedly
suppressed (Figure 7E). When force measurements are normal-
ized to muscle weight (specific force), the differences between
PF and ALI persisted (Figure 7F). These data show that recov-
ery of skeletal muscles from ALI is markedly delayed or sup-
pressed despite complete resolution of lung injury and the
down-regulation of MuRF1 mRNA and protein expression.
They also show that the restoration of muscle mass alone (Fig-
ure 7A) is not sufficient to restore muscle function, evoking the
possibility of intrinsic changes to the contractile apparatus, the
latter consistent with the low levels of MHC expression in ALI
mice at Day 10.
DISCUSSION
It is increasingly recognized that ALI-associated skeletal mus-
cle wasting represents a clinically significant complication that
contributes to the morbidity and mortality of ALI (3–5).
Understanding the molecular mechanisms that promote and
control skeletal muscle wasting associated with ALI is essential
in designing therapeutic approaches targeting this syndrome. As
an important step in that direction, we describe here a mouse
model of ALI that displays some of the key features of human
ALI-associated muscle wasting. These include skeletal muscle
atrophy and weakness that is temporally tied to lung injury and
the persistence of muscle weakness after resolution of lung in-
jury, the later documented to be present in a large percentage of
patients at least 5 years posthospitalization (3–6).
In our study, we show that there is a significant reduction in skel-
etal muscle mass within days of exposure of mice to IT-LPS that is
associated with increased MuRF1 mRNA and protein expression.
This reduction occurs selectively in type II fibers, consistent with
the results of others (32). These changes are associated with high
levels of NF-kB activity in ALI muscles (Figures 4E and 4F),
which others have shown to be important in promoting muscle
wasting associated with tumor cachexia (29) or denervation (27).
Finally, we show that ALI-associated muscle wasting in mice is
markedly suppressed in MuRF1-deficient but not atrogin-deficient
muscles (Figures 4A–4D and 6A–6C). Importantly, our data also
show that muscle weakness persists (Figures 7B–7F) despite
resolution of lung injury and the return of atrophy-associated
mRNAs and proteins to basal levels (Figures 3C–3F). These
Figure 7. Persistence of muscle loss after
complete resolution of lung injury. (A)
Tibialis anterior (TA) wet weights at Day
10 in sham, pair-fed (PF), and acute lung
injury (ALI) TAmuscles are not significantly
different. (B) Cryosections of g-laminin–
stained muscle sections from Day 10
sham, PF, and ALI mice. (C) Mean muscle
fiber analysis of Day 10 muscles shows
similar reductions in PF and ALI diameters
compared with sham controls. yP ,
0.001; n ¼ 5. (D) Representative Western
blots of myosin heavy chain (MyHC) and
muscle ring finger-1 (MuRF1) protein ex-
pression shows that MyHCs remain re-
duced at Day 10, whereas MuRF1 protein
expression is reduced in all groups (Figures
3E and 3F show a time course of MuRF1
protein expression from Days 0–10).
GAPDH ¼ glyceraldehyde phosphate de-
hydrogenase. (E) Force–frequency curves
for Day 10 muscles show that ALI sham
and PF curves are not significantly different
for each other but are both significantly
different from ALI muscle (P ¼ 0.01). (F)
Specific force–frequency curves at Day 10
show a significant difference between PF
and ALI muscles (P ¼ 0.013).
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changes are associated with reductions in the intrinsic contrac-
tility of the muscles (Figure 7F) and persistent suppression of
striated muscle MHCs (Figure 7D).
The biochemical pathways most likely responsible for ALI-
associated muscle wasting are the ubiquitin-mediated proteasomal
and autophagy-lysosomal pathways. In our model, we uncovered
evidence that both pathways were activated, the former shown
in this report to be triggered by increased expression and activity
of themuscle-specific E3 ligase,MuRF1, and the latter presumably
by the marked reduction in food intake in ALI mice that triggered
the up-regulation of selective autophagy-associated genes (33) and
the need to include PF controls in the protocol (see Figure E10).
The use of PF controls is a common practice in the study of
muscle-wasting disorders in which appetite is suppressed or access
to food is limited. It is based on the assumption that the effects of
reduced food intake on muscle mass and function are a separate,
independent, and indirect component of the overall reduction in
muscle mass caused by catabolic processes, such as the activation
of the ubiquitin-mediated proteasomal pathway. Ifmusclewasting in
ALI mice is a composite response of the effects of activating both
proteasomal- and autophagy-mediated molecular and cellular deg-
radation, then muscle wasting should be greater in ALI compared
with PFmuscle. Contrary to that prediction, our data show thatmus-
cle loss and reduction in muscle fiber diameters were similar in ALI
and PF mice (Figures 2A, 2C, and 4B; see Figures E3, E8, and E9).
Furthermore, suppressing MuRF1 expression through genetic inac-
tivation or biochemical suppression in this model prevented the loss
of muscle mass in ALI mice but had no effect in restoring muscle
mass in PF muscles. These data show that all of the muscle wasting
in ALI mice and none of it in PF mice was caused by increased
MuRF1-driven proteasomal activity, excluding a direct contribution
of autophagy to muscle wasting in ALI mice. These data are not
consistent with the assumption that the secondary effects of pair-
feeding are additive with the primary effects of ubiquitin-mediated
proteolysis in muscle, but instead suggest that they may be interde-
pendent and that crosstalk between the two degradative pathways
decides which catabolic pathways are activated or suppressed. One
likely candidate that might mediate this crosstalk is the protein p62
(sequestosome1) (34), which is a negative regulator of autophagy
and a potential binding partner of MuRF1 (35).
In summary, our data demonstrate that ALI in mice produces
marked skeletal muscle wasting and dysfunction similar to that ob-
served in patients withALI.Muscle wasting and dysfunction in this
model is associated with markedly increased NF-kB activity and
MuRF1 transcriptional activation and is suppressed by genetic
inactivation or biochemical suppression of MuRF1. In contrast,
muscle wasting in PF mice is not affected by suppressing MuRF1.
It remains to be determined if MuRF1 is expressed in the skeletal
muscles of humans with ALI and whether blockade of MuRF1
could prevent muscle wasting in these patients. Although recog-
nizing that the results obtained in the mouse may have limited
relevance to ALI in humans, MuRF1 seems to be an attractive
therapeutic target for ALI-associated skeletal muscle wasting.
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